SERINO, Maria Luisa
 Distribuzione geografica
Continente #
NA - Nord America 5.122
EU - Europa 2.180
AS - Asia 1.621
SA - Sud America 155
AF - Africa 21
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 5
Totale 9.112
Nazione #
US - Stati Uniti d'America 5.095
IT - Italia 812
SG - Singapore 719
CN - Cina 528
UA - Ucraina 354
DE - Germania 309
TR - Turchia 262
PL - Polonia 164
GB - Regno Unito 154
BR - Brasile 138
FI - Finlandia 97
SE - Svezia 96
SM - San Marino 44
FR - Francia 35
ID - Indonesia 30
BE - Belgio 25
NL - Olanda 23
CA - Canada 18
CZ - Repubblica Ceca 15
HK - Hong Kong 15
VN - Vietnam 12
RU - Federazione Russa 11
AT - Austria 9
LT - Lituania 9
IQ - Iraq 8
IN - India 7
IR - Iran 7
ZA - Sudafrica 7
MX - Messico 6
PK - Pakistan 6
EG - Egitto 5
IE - Irlanda 5
KE - Kenya 5
A2 - ???statistics.table.value.countryCode.A2??? 4
ES - Italia 4
EU - Europa 4
AR - Argentina 3
AU - Australia 3
BD - Bangladesh 3
CO - Colombia 3
EC - Ecuador 3
RO - Romania 3
VE - Venezuela 3
AL - Albania 2
AZ - Azerbaigian 2
CH - Svizzera 2
DK - Danimarca 2
IL - Israele 2
JP - Giappone 2
LK - Sri Lanka 2
MA - Marocco 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
OM - Oman 2
PY - Paraguay 2
TH - Thailandia 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
GR - Grecia 1
JM - Giamaica 1
KG - Kirghizistan 1
KR - Corea 1
KZ - Kazakistan 1
LU - Lussemburgo 1
MY - Malesia 1
NI - Nicaragua 1
PE - Perù 1
PH - Filippine 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TJ - Tagikistan 1
TN - Tunisia 1
TW - Taiwan 1
UY - Uruguay 1
Totale 9.112
Città #
Woodbridge 658
Fairfield 536
Chandler 483
Jacksonville 404
Santa Clara 312
Houston 290
Singapore 281
Ann Arbor 261
Ashburn 258
Seattle 232
Wilmington 224
Warsaw 163
Cambridge 157
Izmir 150
Ferrara 119
Nanjing 112
Beijing 107
Milan 95
Princeton 86
Boardman 71
Shanghai 57
New York 56
San Diego 46
Bremen 38
Shenyang 34
Dearborn 32
Hebei 30
Jakarta 29
Rome 28
Nanchang 26
Brussels 23
Changsha 23
Los Angeles 23
Helsinki 21
Jiaxing 20
Redwood City 20
Düsseldorf 19
London 18
Jinan 15
Mountain View 15
Munich 15
Naples 15
Bologna 14
Hong Kong 14
Brno 13
Falls Church 13
Tianjin 13
Dong Ket 12
Des Moines 11
Meda 11
Guangzhou 10
Kunming 10
Toronto 10
Washington 10
Auburn Hills 9
Council Bluffs 9
Frankfurt am Main 9
Napoli 9
Nuremberg 9
Orange 8
Pescara 8
Augusta 7
Brescia 7
Domagnano 7
Florence 7
Ottawa 7
São Paulo 7
Ansbach 6
Changchun 6
Dogana 6
Ningbo 6
Norwalk 6
Pavia 6
Redmond 6
San Marino 6
Turin 6
Ardabil 5
Baghdad 5
Duncan 5
Hangzhou 5
Rio de Janeiro 5
Brasília 4
Calvisano 4
Ferrara di Monte Baldo 4
Lauterbourg 4
Leeds 4
Monmouth Junction 4
San Mateo 4
Addison 3
Altopascio 3
Campinas 3
Curitiba 3
Davoli 3
Hefei 3
Lahore 3
Lodi 3
Marino 3
Monticello Conte Otto 3
Padova 3
Portsmouth 3
Totale 5.989
Nome #
ProC Global test>ProC Complete test: una modificazione del Global test per la misurazione contemporanea della attività della PC, della PS, e del fenotipo Leiden. 488
Ricerche metodologiche sul dosaggio del cofattore Ristocetinico per la diagnosi di morbo di von Willebrand. 224
Inherited genetic predispositions in F13A1 and F13B genes predict abdominal adhesion formation: identification of gender prognostic indicators 183
Gene-gene interactions among coding genes of iron-homeostasis proteins and APOE-alleles in Cognitive Impairment Diseases 182
The active metabolite of warfarin (3′-hydroxywarfarin) and correlation with INR, warfarin and drug weekly dosage in patients under oral anticoagulant therapy: A pharmacogenetics study 169
Effect of factor XIII-A G185T polymorphism on visual prognosis after photodynamic therapy for neovascular macular degeneration 166
Factor XIII contrasts the effects of metalloproteinases in human dermal fibroblast cultured cells 157
Thrombosis of the cerebral veins and sinuses in acute promyelocytic leukemia after all-trans retinoic acid treatment: a case report. 155
Coagulation factor XIIIA (F13A1): Novel perspectives in treatment and pharmacogenetics 146
Coexistence of antithrombin deficiency, factor V Leiden and hyperhomocysteinemia in a thrombotic family. 143
Factor XIII-A dynamics in acute myocardial infarction: a novel prognostic biomarker? 143
Factor XIII V34L polymorphism modulates the risk of chronic venous leg ulcer progression and extension 142
F13A1 gene variant (V34L) and residual circulating FXIIIA levels predict short-and long-term mortality in acute myocardial infarction after coronary angioplasty 141
Blood Group O Protects against Inhibitor Development in Severe Hemophilia A Patients 140
A common mutation in the gene for coagulation factor XIII-A (Val34Leu): A risk factor for primary intracerebral hemorrhage is protective against atherothrombotic diseases 138
A novel mutation (Leu817Pro) causing type 2A von Willebrand disease. 137
COVID-19 and individual genetic susceptibility/receptivity: Role of ACE1/ACE2 genes, immunity, inflammation and coagulation. might the double x-chromosome in females be protective against SARS-COV-2 compared to the single x-chromosome in males? 132
Coexistence of factor V G1691A and factor II G20210A gene mutations in a thrombotic family is associated with recurrence and early onset of venous thrombosis 131
A modified functional Global test to measure protein C, protein S activities and the activated protein C-resistance phenotype. 129
A photometric assay for factor-XIII in chronic hepatopathies. 126
Different anticoagulant response to activated protein C (APC test) and to Agkistrodon Contortix venom (ACV test) in a family with FV-R506Q substitution 124
A photometric method for the dosage of factor XIII applied to the study of chronic hepatopathies. 124
Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories 124
Deletion of exons 26-34 (domain D3-A3) of von Willebrand-factor gene in the von Willebrand disease type-II. 119
null 118
The reduced sensitivity of the ProC (R) Global test in protein S deficient subjects reflects a reduction in the associated thrombotic risk 117
Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy 117
Clinical observations on the relationship between idiopathic thrombocytopenic purpura lupus anticoagulant and anticardio-lipin antibody syndrome. 115
Cancers in patients with hemophilia: a retrospective study from the Italian Association of Hemophilia Centers 114
Spectrum of F8 gene mutations in haemophilia A patients from a region of Italy: Identification of 23 new mutations 113
FXIII levels and genotypes in myocardial infarction: a potential novel prognostic biomarker? 113
Mortality and causes of death in Italian persons with haemophilia, 1990-2007 112
Low folate levels and thermolabile methylenetetrahydrofolate reductase as primary determinant of mild hyperhomocystinemia in normal and thromboembolic subjects 111
C677T/A1298C MTHFR Gene Mutations, Homocysteine, Folate Levels and MTHFR Activity, in Normal Subjects and Cases with Myocardial Infarction 110
Common gene polymorphisms in the metabolic folate and methylation pathway and the risk of acute lymphoblastic leukemia and non-Hodgkin's lymphoma in adults 108
Center-Related Determinants of VKA Anticoagulation Quality: A Prospective, Multicenter Evaluation 105
null 102
Factor XIIIA V34L and Factor XIIIB H95R Gene Polymorphisms: Effects on the Risk of Myocardial Infarction and on Survival. 101
Una "rete" per proteggere il cuore. (FAR 2013) 99
Maternal Haplotypes in DHFR Promoter and MTHFR Gene in Tuning Childhood Acute Lymphoblastic Leukemia Onset-Latency: Genetic/Epigenetic Mother/Child Dyad Study (GEMCDS) 97
Common Polymorphisms in the Metabolic Folate Pathway Decrease the Risk of Acute Lymphocytic Leukemia in Adults 95
An Italian Family with a Novel Mutation Causing Type 2A von Willebrand Disease and with Reduced Levels of von Willebrand Factor not Linked with the von Willebrand Factor Gene. 94
A modified functional Global test to measure PC, PS activities and the APC-Resistance phenotype. 92
C677T Substitution in the Methylenetetrahydrofolate Reductase Gene as a Risk Factor for Venous Thrombosis and Arterial Disease in Selected Patients. 92
null 91
A web-based clinical record 'xl'Emofilia® 'for outpatients with haemophilia and allied disorders in the region of Emilia-Romagna: Features and pilot use 91
Caratterizzazione di una nuova mutazione nell’esone 28 del gene del fattore di von Willebrand (FvW) responsabile della malattia di vW di tipo IIA. 89
Factor XIII-A Gene Mutation (Val34Leu) and Arterial Vascular Disease 88
A de novo antithrombin mutation found in a patient with deep vein thrombosis and vascular abnormalities. 88
Common Polymorphisms in the Metabolic Folate Pathway Decrease the Risk of Acute Lymphocitic Leukemia in Adults 87
Effect of factor XIII Val34Leu polymorphism on plasma clot formation: crosslinking functions and clot longevity properties. 86
A Common mutation in the gene for coagulation factor XIII-A (V34L): a risk factor for hemorrhagic disorders it is protective against atherothrombotic diseases. 85
null 85
Dihydrofolate reductase (DHFR) 19-bp ins/del polymorphism and methylenetetrahydrofolate reductase (MTHFR) C677T in coronary heart disease patients: potential intracellular folate unbalancing. 83
Malattie emorragiche vascolari. 83
FXIII Levels in Myocardial Infarction: a Potential Novel Prognostic Biomarker? 82
Anticardiolipin antibody-related thrombocytopenia: persistent remission after splenectomy. 82
null 80
Resistance to activated protein C and low levels of protein S activity in nine thrombophilic families: a correct diagnosis. 80
Common Gene Polymorphisms in the Metabolic Folate and Methylation Pathway and the Risk of Acute Lymphoblastic Leukemia and non-Hodgkin’s Lymphoma 79
Factor V Levels in a Cohort of Patients Eligible for Oral Anticoagulant Therapy. 79
Coexistence of antitrhombin deficency, factor V Leiden and hereditary hyperhomocyst(e)inemia in a thrombotic family. 78
High protein C plasma levels affect the response to exogenous preactivated protein C and enhance that to endogenous Protac-mediated activated protein C. 77
Factor XIIIA-V34L and Factor XIIIB-H95R Gene Variants and Survival after Myocardial Infarction. 73
Thrombotic risk in thalassemic patients. 71
Low folate levels and thermolabile MTHFR as primary determinant of mild Hyperhomocysteinemia in normal and thromboembolic subjects. 68
Differente risposta alla Proteina C attivata della muatazione R506Q del fattore V della coagulazione (FV Leiden) in due generazioni della stessa famiglia. 68
Bassi livelli di Proteina S e Resistenza alla Proteina C attivata in dieci famiglie italiane. 65
FXIII-A V34L and FXIII-B H95R gene polymorphism: effects on the efficacy of thrombolytic therapy in acute myocardial infarction. 65
Low Sensitivity to Endogenous Activated Protein C in Protein S Deficient Subjects Reflects a Reduction in the Thrombotic Risk 64
MTHFR C677T/A1298C, MS A2756G and MTRR A66G Gene Polymorphisms: Effects on Homocysteine Levels and Risk of Miocardial Infarction 63
null 61
Determinazione dell’anticoagulante lupico (LAC) con un metodo al caolino automatizzato. 59
Detection of a Protein C Gene Mutation Present in the Asymptomatic and not in the Thrombosis-Prone Lineage. 57
Favourable recombinant factor IX pharmacokinetics outcomes in severe hemophilia B patients with FIX activation site mutations 57
MTHFR Specific Activity, Homocysteine and Folate Levels in Subjects with Thermolabile MTHFR (C677T) 56
Cis-segregation of c.1171c>t stop codon (p.r391*) in serpinc1 gene and c.1691g>a transition (p.r506q) in f5 gene and selected gwas multilocus approach in inherited thrombophilia 56
F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes 55
The G to T Point Mutation (Val34Leu) in the Factor XIII-A Subunit Gene in Venous Leg Ulcers 54
Host genetics impact on SARS-CoV-2 vaccine-induced immunoglobulin levels and dynamics: The role of TP53, ABO, APOE, ACE2, HLA-A, and CRP genes 52
Conteggio piastrinico e terapia sostitutiva in un paziente con Malattia di von Willebrand tipo 2B. 52
Sui rapporti tra anticorpi anticardiolipina e ß-2-glicoproteina I plasmatica. 50
null 49
Common Factor XIII Gene Polymorphisms In Venous Leg Ulcers. 48
Genotype and PK Hemophilia B International Study (GePKHIS) - A progress Report 48
Piastrinopenia da anticorpi anticardiolipina: remissione persistente dopo splenectomia. 47
Factor XIIIA-V34L and factor XIIIB-H95R gene variants: effects on survival in myocardial infarction patients. 45
Treatment outcome and postoperative complications of mucogingival surgery in a case of type I von Willebrand disease 43
DHFR 19-bp insertion/deletion polymorphism and MTHFR C677T in adult acute lymphoblastic leukaemia: is the risk reduction due to intracellular folate unbalancing? 42
Epigenetic role of LINE-1 methylation and key genes in pregnancy maintenance 41
Different anticoagulant response to activated protein C (APC-test) and to Agkistrodon Contortix Venom (ACV-test) in a family with FV-R506Q substitution 37
Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey. 27
miRNAs Epigenetic Tuning of Wall Remodeling in the Early Phase after Myocardial Infarction: A Novel Epidrug Approach 26
GRB 130427A: a Nearby Ordinary Monster 25
Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. 24
In vitro and ex vivo rescue of a nonsense mutation responsible for severe coagulation factor V deficiency 19
Gene Dosage of F5 c.3481C>T Stop-Codon (p.R1161Ter) Switches the Clinical Phenotype from Severe Thrombosis to Recurrent Haemorrhage: Novel Hypotheses for Readthrough Strategy 11
Totale 9.259
Categoria #
all - tutte 44.085
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 363
Totale 44.448


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020294 0 0 0 0 0 0 0 0 0 162 81 51
2020/20211.243 98 103 46 131 97 139 51 140 46 181 151 60
2021/2022837 30 77 46 41 65 36 37 51 28 86 104 236
2022/20231.093 106 104 21 131 189 156 60 109 111 9 63 34
2023/2024605 53 69 26 26 72 94 28 49 9 21 25 133
2024/20251.741 72 45 175 91 312 188 97 122 467 172 0 0
Totale 9.259